COMP <GO>
LGND vs LLY // RSI-14 & 200D SMA MOMENTUM
Ligand Pharmaceuticals Incorporated (NASDAQ) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: LGND 3
— LLY 12
▲ RSI-14 & 200D SMA MOMENTUM LEADER: LLY
LAST: $322.75 (+1.71%) • MKT CAP: $6.33B
rsi-technicals
63.4
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
rsi-technicals
77.9
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (LGND VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | LGND | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 83.64% | -42.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 3.00% | 32.36% | -29.36 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 95.0x | 36.4x | +58.58 | LLY | /valuation <GO> |
| Free Cash Flow Yield | 0.77% | 2.30% | -1.53 | LLY | /fcf-yield <GO> |
| Operating Margin | 15.30% | 40.21% | -24.91 | LLY | /operating-margins <GO> |
| Net Profit Margin | 46.40% | 31.90% | +14.50 | LGND | /net-margins <GO> |
| Revenue Growth (YoY) | 60.40% | 45.51% | +14.89 | LGND | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.40 | 9.29 | -0.89 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 6.77% | +0.33 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 63.4 | 77.9 | -14.49 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.07 | 0.51 | +0.56 | LGND | /macro-sensitivity <GO> |
| Forward P/E Multiple | 42.7x | 26.3x | +16.45 | LLY | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $6.33B | $1.33T | -$1.33T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | LGND REV | LLY REV | LGND GROSS % | LLY GROSS % | LGND FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $268.1M | $65.18B | 44.0% | 83.0% | $48.9M | $16.81B |
| FY 2024 | $167.1M | $45.04B | 44.0% | 81.3% | $95.2M | $8.82B |
| FY 2023 | $131.3M | $34.12B | 44.0% | 79.3% | $43.7M | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
LGND // BETA 1.07
LLY // BETA 0.51